Drug Therapy Protocols: Glyceryl trinitrate

<table>
<thead>
<tr>
<th><strong>Policy code</strong></th>
<th>DTP_GTN_1119</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Date</strong></td>
<td>November, 2019</td>
</tr>
<tr>
<td><strong>Purpose</strong></td>
<td>To ensure a consistent procedural approach to glyceryl trinitrate administration.</td>
</tr>
<tr>
<td><strong>Scope</strong></td>
<td>Applies to all Queensland Ambulance Service (QAS) clinical staff.</td>
</tr>
<tr>
<td><strong>Health care setting</strong></td>
<td>Pre-hospital assessment and treatment.</td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Applies to all ages unless specifically mentioned.</td>
</tr>
<tr>
<td><strong>Source of funding</strong></td>
<td>Internal – 100%</td>
</tr>
<tr>
<td><strong>Author</strong></td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td><strong>Review date</strong></td>
<td>November, 2022</td>
</tr>
</tbody>
</table>

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

**Disclaimer**

The Digital Clinical Practice Manual is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.


This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en](http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en)

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au
**Drug class**
Vasodilator

**Pharmacology**
Glyceryl trinitrate (GTN) is a potent vasodilator that decreases preload by increasing venous capacity, pooling venous blood in the peripheral veins, reducing ventricular filling pressure and decreasing arterial blood pressure (after load). Because of this cascade it also causes vasodilation in coronary arteries that are in spasm and may assist the redistribution of blood flow along the collateral channels in the heart.\[1-3\]

**Metabolism**
GTN is readily absorbed and metabolised by the liver.\[1\]

**Indications**
- **Suspected ACS** (with pain)
- **Acute cardiogenic pulmonary oedema**
- **Autonomic dysreflexia**
  (with a systolic BP ≥ 160 mmHg)\[4-5\]
- **Irukandji syndrome**
  (with a systolic BP ≥ 160 mmHg)

**Contraindications**
- Allergy and/or Adverse Drug Reaction
- Heart rate < 50 OR > 150 beats per minute
- Systolic BP < 100 mmHg
- Acute CVA
- Head trauma
- Phosphodiesterase inhibitor medication administration (e.g. Viagra® or Levitra®) in the previous 4 days\[6\]

**Precautions**
- Suspected inferior AMI
- Cerebral vascular disease
- Risk of hypotension and/or syncope
- Intoxication (GTN effects are enhanced)
- Phosphodiesterase inhibitor medication administration (e.g. Viagra® or Levitra®) in the previous 24 hours\[6\]

**Side effects**
- Dizziness
- Hypotension
- Syncope
- Reflex tachycardia
- Vascular headaches
### Glyceryl trinitrate

#### Presentation
- Spray (sublingual), 400 microg/dose, 200 doses, nitrolingual pump spray
- Ampoule, 50 mg/10 mL glycercyl trinitrate

#### Onset, Duration, Half-life

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Duration</th>
<th>Half-life</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUBLING spray</td>
<td>&lt; 2 minutes</td>
<td>20–30 minutes</td>
<td>5.5 minutes</td>
</tr>
<tr>
<td>Ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Schedule
- SUBLING spray – S3 (Therapeutic poisons).
- Ampoule, 50 mg/10 mL – S4 (Restricted drugs).

#### Routes of administration
- Sublingual (SUBLING)
- Intravenous infusion (IV INF)

#### Special notes
- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the QAS Clinical Consult and Advice Line.
- Sublingual GTN is the first line treatment for ACS, however IV GTN should be considered as part of the management regime for all patients unresponsive to sublingual GTN, narcotics and/or β blockers.
- Research has identified that GTN potency may be reduced due to the migration of GTN into certain administration sets. IV INF doses should be titrated according to patient response despite the container and giving set used.
- Prepared GTN IV infusion solutions are stable in polypropylene syringes for 24 hours.
- Some patients with normal or low left ventricular filling pressures or pulmonary capillary pressure may be hypersensitive to the effects of GTN and may respond to IV infusion doses from 5 microg/min.
- CCP ESoP aeromedical officers are to display extreme caution when ceasing GTN infusions due to the potential of rebound symptoms.
- GTN is the first line treatment for autonomic dysreflexia, however morphine should be considered as part of the management regime, if the patient is unresponsive to initial treatment.
- 50 mg/10 mL GTN ampoules are not currently supplied by the QAS warehouse – for procurement information please refer to the QAS Drug Management Code of Practice.
- All cannulae and IV lines must be flushed thoroughly with sodium chloride 0.9% following each medication administration.
### Adult dosages

<table>
<thead>
<tr>
<th>Suspected ACS (with pain)</th>
<th>Adult dosages (cont.)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AT P ACP2 CCP</strong> SUBLING</td>
<td><strong>Autonomic dysreflexia</strong> (with a systolic BP ≥ 160 mmHg)</td>
</tr>
<tr>
<td><strong>IV INF CCP</strong></td>
<td><strong>Irukandji syndrome</strong> (with a systolic BP ≥ 160 mmHg)</td>
</tr>
<tr>
<td></td>
<td>400 microg Repeated at 5 minute intervals. No maximum dose.</td>
</tr>
<tr>
<td></td>
<td><strong>ACP1 ACP2 CCP</strong> SUBLING 400 microg Repeated at 5 minute intervals. No maximum dose.</td>
</tr>
<tr>
<td></td>
<td><strong>ACP1 ACP2 CCP</strong> SUBLING</td>
</tr>
<tr>
<td></td>
<td><strong>ACP1 ACP2 CCP</strong> SUBLING</td>
</tr>
</tbody>
</table>

**Suspected ACS**

- **Autonomic dysreflexia** (with a systolic BP ≥ 160 mmHg)
- **Irukandji syndrome** (with a systolic BP ≥ 160 mmHg)

**Adult dosages**

- **400 microg**
- Repeated at 5 minute intervals.
- **No maximum dose.**

**Paediatric dosages**

- **Autonomic dysreflexia** (with a systolic BP ≥ 160 mmHg)
- **Irukandji syndrome** (with a systolic BP ≥ 160 mmHg)

**Syringe preparation:** Mix 30 mg (6 mL) of GTN with 44 mL of glucose 5% in a 50 mL syringe to achieve a final concentration of 600 microg/mL. Ensure all syringes are appropriately labelled. Administer via syringe driver.

**Note:** In all other instances, QAS officers are **NOT** authorised to administer GTN to paediatric patients.
Glyceryl trinitrate instructions for use

1. Position the patient in a sitting or semi-reclined position.

2. Remove the plastic cover from the GTN spray bottle, thoroughly wipe the entire container including the nozzle using an alcohol swab and allow to dry.

3. If using a new bottle, prime the pump by holding the bottle upright, facing away from the patient and bystanders & depress the nozzle 5 times (do not shake the bottle). If first use for the day, prime by spraying once.

4. Instruct the patient to open their mouth wide and lift their tongue to the roof of their mouth (some patients may have difficulty and may require a demonstration from the clinician).

5. Bring the bottle to within approximately 3–4 cm from the patient (without contact) with the nozzle aimed directly under the patient’s tongue and steadily depress the nozzle once.

6. Recap the bottle after each administration.

7. If the nozzle inadvertently comes into direct contact with the patient, the bottle must be discarded after the last administration on the current patient.

8. After the last administration, thoroughly wipe the entire bottle including the nozzle and inside of the cap using an alcohol swab.

9. Recap the bottle and store in the drug kit for the next patient.